title: Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study.
authors.affiliation: Department of Immunotechnology, Lund University, Lund, Sweden.|CREATE Health, Lund University, Lund, Sweden.
authors.forename: F
authors.initials: F
authors.lastname: Pauly
authors.affiliation: Department of Oncology, Lund University, Skåne University Hospital, Lund, Sweden.
authors.forename: K
authors.initials: K
authors.lastname: Fjordén
authors.affiliation: Department of Oncology, Helsinki University Hospital, Helsinki, Finland.
authors.forename: S
authors.initials: S
authors.lastname: Leppä
authors.affiliation: Department of Oncology, Oslo University Hospital, Oslo, Norway.
authors.forename: H
authors.initials: H
authors.lastname: Holte
authors.affiliation: Department of Medicine, Karolinska University Hospital, Stockholm, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: Björkholm
authors.affiliation: Department of Oncology, Haukeland University Hospital, Bergen, Norway.
authors.forename: Ø
authors.initials: Ø
authors.lastname: Fluge
authors.affiliation: Department of Hematology, Roskilde Hospital, Roskilde, Denmark.
authors.forename: L
authors.initials: L
authors.lastname: Møller Pedersen
authors.affiliation: Department of Oncology, Lund University, Skåne University Hospital, Lund, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: Eriksson
authors.affiliation: Department of Immunotechnology, Lund University, Lund, Sweden.|CREATE Health, Lund University, Lund, Sweden.
authors.forename: A
authors.initials: A
authors.lastname: Isinger-Ekstrand
authors.affiliation: Department of Immunotechnology, Lund University, Lund, Sweden.|CREATE Health, Lund University, Lund, Sweden.
authors.forename: C A K
authors.initials: CA
authors.lastname: Borrebaeck
authors.affiliation: Department of Oncology, Lund University, Skåne University Hospital, Lund, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: Jerkeman
authors.affiliation: Department of Immunotechnology, Lund University, Lund, Sweden.|CREATE Health, Lund University, Lund, Sweden.
authors.forename: C
authors.initials: C
authors.lastname: Wingren
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001798:Blood Proteins / Q000032:analysis / Q000276:immunology; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016130:Immunophenotyping / Q000379:methods*; D008224:Lymphoma, Follicular / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000379:methods; D011239:Prednisolone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D040081:Protein Array Analysis / Q000379:methods*; D040901:Proteomics / Q000379:methods; D012307:Risk Factors; D000069283:Rituximab; D016019:Survival Analysis; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D001798:Blood Proteins; C571759:R-CHOP protocol; D003561:Cytarabine; D000069283:Rituximab; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D011241:Prednisone; D008727:Methotrexate